Yue Liu
Valentina Echeverria
Youhua Xu- 1Cardiovascular Disease Centre, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
- 2Cardiovascular Disease Centre, National Clinical Research Center for Chinese Medicine Cardiology, Beijing, China
- 3Laboratorio de Neurobiología, Facultad de Ciencias de la Salud, Universidad San Sebastián, Concepción, Chile
- 4Research and Development Department, Bay Pines VA Healthcare System, Bay Pines, FL, United States
- 5State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, Macau
Editorial on the Research Topic Medicinal
Medicinal Plants for Cardiovascular and Neurodegenerative Aging-Related Diseases: From Bench to Bedside
Aging is a progressive and multi-step degeneration in the physiological functions and metabolic processes of living organisms until death. It represents the main risk factors for a number of debilitating diseases and contributes to increase in mortality (Ahadi et al., 2020). With increasing life expectancy, the number of patients with aging related diseases will continue to rise, leading to an increased healthcare burden. There is a need for new therapies to treat this growing number of patients in a manner that is effective and sustainable (Liu and Chen, 2012). Aging presents profound physiological changes in the cardiovascular system and the relationship between cardiovascular pathology and neurodegenerative diseases is well known (Luo et al., 2020). Ischemic events due to cardiac pathology or stroke can lead to cardiovascular dementia and the development of Alzheimer’s disease (Daniele et al., 2020). Cardiac pathology has also been found to be associated with other neurodegenerative conditions such as Huntington’s disease (Critchley et al., 2018). Interestingly, it is hypothesized that factors systemically linking these pathologies are associated with neuroinflammation and oxidative stress pathways (Liu et al., 2019; Tian et al., 2019). While the underlying mechanisms in the aging heart or brain are still unclear, greater research is needed to test the potential for pharmacological interventions in these pathways.
Natural plants have been associated with traditional medical approaches for thousands of years all over the world. Great varieties of plants have persisted in such usage for medicinal treatments in various cultures and many new drugs have been discovered from herbal sources (Liu et al., 2013; Liu and Liu, 2020). The 2015 Nobel Prize awarded to Professor Tu, a Chinese pharmaceutical scientist, for the discovery of artemisinin renewed global interest in herbal medicine, and potential integration of such approaches into evidence-based medical systems (Tu, 2011). Medicinal plants have shown to be beneficial in decreasing the occurrence or delay of the neurodegenerative process induced by cardiovascular and mixed pathological events. It is believed that many of the medicinal herbs have anti-aging properties (Zhao et al., 2020), but the mechanisms and safety remain unclear.
This Research Topic is a collection of nineteen articles adapting a critical approach designed to robustly test the clinical effects, mechanisms and safety of adequately-characterized herbal medicine and their active components for aging-related diseases, in particular, cardiovascular and neurodegenerative diseases.
Alzheimer’s disease (AD) is the most common neurodegenerative disorder associated with aging that causes memory, thinking and behavior disorders. Currently, FDA-approved anti-AD drugs (rivastigmine, galantamine, donepezil, memantine) are potential effective in the short term but are unable to halt or reverse disease progression (Dong et al., 2019). In November 2019, Sodium oligomannate received its first approval in China for the treatment of mild to moderate AD to improve cognitive function (Syed Yahiya, 2020), therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit AD progression (Wang et al., 2019), but there is some controversy in China (Rao, 2020; Wang et al., 2020). In this Research Topic, there are three research articles and two review articles describing the potential efficacy and related mechanisms of medicinal plants for AD or brain aging. An research article by Yang et al. evaluated the in vitro and in vivo effects of a traditional Chinese medicinal formula named Yizhiqingxin formula (YQF) on autophagy, the authors found that YQF could improve spatial learning in APP/PS1 mice and ameliorate the accumulation of Aβ while promoting autophagy via mTOR pathway modulation. Peng et al.’s article studied the molecular mechanisms of another traditional Chinese medicinal formula, Baizhu decoction (BZD) for AD, they found that middle- and high-doses of BZD ameliorated the behavioral aspects of 5xFAD transgenic mice in elevated plus maze, Y maze and Morris water maze tests with reduced BACE1 and PS1, resulting in a reduction of Aβ plaques and oxidative damage. Study by Wang et al. showed that β-Asarone, the main constituent of Acorus tatarinowii Schott, significantly dose-dependently increased cell proliferation and decreased cytotoxicity, inhibited SA-bGal and improved cell senescence in PC12 cell AD model. In a literature review, Balkrishna et al. reviewed the phytochemical profile, pharmacological attributes and medicinal information of Convolvulus prostratus (a nootropic herb used in traditional medicinal systems) with comprehensive research gap analysis, Convolvulus prostratus is mainly endowed with neuroprotective, nootropic and neuro-modulatory activities without any signs of toxicity and neurodegeneration up to a dose of 2000 mg/kg in mice. Another review article by Martínez-Coria et al. analyzed the most important pharmacological actions of dihydromyricetin (one of the main flavonoids of some Asian medicinal plants), including its antioxidant, anti-inflammatory and neuroprotective actions, as well as its ability to restore GABA neurotransmission, improve motor and cognitive behavior.
One research article by Fu et al. studied neuroprotective effects of Qingnao dripping pills(QNDP), a traditional Chinese prescription, for Ischemic stroke. The authors found that QNDP had neuroprotective effects against cerebral ischemia via inhibiting NLRP3 inflammasome signaling pathway, and was a potential candidate for the future treatment of ischemic stroke.
Heart failure (HF) is the terminal state of all cardiovascular diseases, and there is limited effective drug up to now (McMurray et al., 2019; Triposkiadis et al., 2019). The discovery of potential drugs for the treatment of heart failure from medicinal plants is of great clinical value. Lu et al. explore the effect of Qishen Granule (an effective Chinese medicine for treating heart failure) on the release of splenic monocytes, the recruitment of monocytes into heart tissues and the differentiation of macrophages under ischemic conditions. The authors reported that compounds of Chinese medicine have synergistic effects on cardiac and splenic organs through regulating differentiation of monocytes/macrophages in inhibiting myocardial remodeling. Li et al. reported that administration of Shengmai (used to treat acute and chronic heart failure in China), a traditional Chinese medicine extracted from Panax ginseng C.A. Mey., Ophiopogon japonicus (Thunb.) Ker Gawl., and Schisandra chinensis (Turcz.) Baill., suppressed ang II–induced cardiomyocyte hypertrophy and apoptosis via activation of the AMPK signaling pathway through an energy dependent mechanisms. Another TCM, Shenfu injection (SFI) has been widely used for the treatment of shock and HF in China. The study by Zhu et al. showed that the vasodilation effect of SFI in thoracic aorta is mediated entirely by enhancing eNOS, activity through the PI3K/Akt signaling pathway, providing novel knowledge on the effect of SFI on shock and HF for future clinical applications. Yixinshu Capsules (YXSC) are widely used in China for the treatment of heart failure (HF) with better clinical efficacy, but the therapeutic mechanisms are not well understood. In the study by Xu et al., a metabonomic approach based on integrated UPLC-Q/TOF-MS technique and MALDI-MS was utilized to explore potential metabolic biomarkers increasing the understanding of HF and assessing the potential mechanisms of YXSC against HF, they proposed strategy may contribute to the understanding of the complex pathogenesis of ischemia-induced HF and the potential mechanism of YXSC.
Many medicinal plants do not enter the blood after they are taken orally, growing evidence suggest the role of the gut microbiota as targets for the multifunctional role of medicinal plants for cardiovascular diseases (CVD) (Gong et al., 2020). There are three research articles focused on the changing characteristics of gut microbiota to elucidate the mechanisms of medicinal plants in the treatment of cardiovascular disease. Zhang et al. reported that long-term administration of Naoxintong capsule, a Chinese medicine, increased the diversity of gut microbiota, influenced the microbiome structure and composition stably, and revered the increase of the ratio of the Firmicutes to Bacteroidetes in relative abundance, inhibited the development of cardiovascular diseases by ameliorating high-fat diet-induced metabolic disorders and partly through improving gut microbiota. Wu M. et al. observe the effects of high or low doses of berberine on atherosclerosis and gut microbiota modulation, their study found that anti-atherosclerotic action of berberine may be partly attributed to changes in composition and functions of gut microbiota which may be associated with anti-inflammatory and metabolism of glucose and lipid. The study by Wu D. et al. provides for the first time the morphological, biochemical, and molecular evidence supporting the protective effects of baicalin (the major flavonoid component of S. baicalensis Georgi) on the intestinal integrity in the spontaneously hypertensive rats, which may help better understand the therapeutic actions of S. baicalensis Georgi in the treatment of hypertension.
An important feature of this Research Topic collection, many well-known scholars have contributed a lot of wonderful literature reviews about medicinal plants for aging-related cardiovascular and neurodegenerative diseases. Souza-Junior et al. discuss the ethnobotanical characteristics, phytochemical constitution, and cardiovascular and neurological properties of A. canelilla, systematizing the knowledge about the species and proposing new perspectives for research and development. Shaito et al. overview the data on the ethnopharmacological therapeutic potentials and medicinal properties against CVDs (myocardial infarction, hypertension, peripheral vascular diseases, coronary heart disease, cardiomyopathies, and dyslipidemias) of Ginseng, Ginkgo biloba, Ganoderma lucidum, and Gynostemma pentaphyllum. Michel et al. reviewed the potential use of medicinal plants from Asteraceae and Lamiaceae Plant Family in CVDs. Atherosclerosis is the main pathological mechanism of aging-related cardiovascular and neurodegenerative diseases, characterized by changes of blood lipids profile and inflammation in vessel wall. Kirichenko et al. reviewed the databases PubMed and Scopus (until November, 2019) to investigate the medicinal plants possessing anti-atherosclerotic activity in experimental and clinical studies. Wu M. et al. summarize the blood lipid lowering, anti-oxidative, anti-inflammatory, and vascular endothelial protection by hawthorn and its extracts, providing a potential use for atherosclerosis. This Research Topic also includes a systematic preclinical review of the effect of Notoginsenoside R1 (NGR1) for ischemia/reperfusion injury. The study by Tong et al. showed the organ protection effect of NGR1 after I/R injury, suggesting that NGR1 can potentially become a novel drug candidate for ischemic diseases.
From the above-mentioned 19 articles, this Research Topic provides recent evidence about efficacy, mechanisms, and safety of medicinal plants for cardiovascular and neurodegenerative aging-related diseases. We hope this topic will help to achieve a deeper understanding of the effect of medicinal plants for aging-related diseases.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.
Funding
VE was supported by a Grant Fondecyt 1190264 from ANID, Chile.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The guest editors of this Research Topic acknowledges the efforts and contribution of authors, reviewers, and journal senior editors for their sincere efforts.
References
Ahadi, S., Zhou, W., Schüssler-Fiorenza Rose, S. M., Sailani, M. R., Contrepois, K., Avina, M., et al. (2020). Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat. Med. 26 (1), 83–90. doi: 10.1038/s41591-019-0719-5
Critchley, B. J., Isalan, M., Mielcarek, M. (2018). Neuro-Cardio Mechanisms in Huntington’s Disease and Other Neurodegenerative Disorders. Front. Physiol. 9, 559. doi: 10.3389/fphys.2018.00559
Daniele, G., DiLucia, S., Masci, P. G., Del Monte, F. (2020). Heart and Brain: Complex Relationships for Left Ventricular Dysfunction. Curr. Cardiol. Rep. 22 (8), 72. doi: 10.1007/s11886-020-01318-w
Dong, Y., Li, X., Cheng, J., Hou, L. (2019). Drug development for Alzheimer’s disease: microglia induced neuroinfammation as a target? Int. J. Mol. Sci. 20 (3), 558. doi: 10.3390/ijms20030558
Gong, X., Li, X., Bo, A., Shi, R.-Y., Li, Q.-Y., Lei, L.-J., et al. (2020). The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: A review. Pharmacol. Res. 157, 104824. doi: 10.1016/j.phrs.2020.104824
Liu, Y., Chen, K. J. (2012). Atherosclerosis, vascular aging and therapeutic strategies. Chin. J. Integr. Med. 18 (2), 83–87. doi: 10.1007/s11655-012-0996-z
Liu, Y., Liu, Y. (2020). Herbal Medicine for Slowing Aging and Cardiovascular Risk: Mechanisms and Safety. Curr. Vasc. Pharmacol. 18 (4), 305–306. doi: 10.2174/157016111804200507075606
Liu, Y., Yin, H., Chen, K. (2013). Platelet proteomics and its advanced application for research of blood stasis syndrome and activated blood circulation herbs of Chinese medicine. Sci. China Life Sci. 56 (11), 1000–1006. doi: 10.1007/s11427-013-4551-8
Liu, Y., Weng, W., Gao, R., Liu, Y. (2019). New Insights for Cellular and Molecular Mechanisms of Aging and Aging-Related Diseases: Herbal Medicine as Potential Therapeutic Approach. Oxid. Med. Cell Longev. 2019, 4598167. doi: 10.1155/2019/4598167
Luo, H., Zhang, R., Krigman, J., McAdams, A., Ozgen, S., Sun, N. (2020). A Healthy Heart and a Healthy Brain: Looking at Mitophagy. Front. Cell Dev. Biol. 8, 294. doi: 10.3389/fcell.2020.00294
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 381 (21), 1995–2008. doi: 10.1056/NEJMoa1911303
Rao, Y. (2020). Omission of previous publications by an author should be corrected. Cell Res. 30 (9), 819. doi: 10.1038/s41422-020-0344-3
Syed Yahiya, Y. (2020). Sodium Oligomannate: First Approval. J. Drugs 80 (4), 441–444. doi: 10.1007/s40265-020-01268-1
Tian, J., Popal, M. S., Zhao, Y., Liu, Y., Chen, K., Liu, Y. (2019). Interplay between Exosomes and Autophagy in Cardiovascular Diseases: Novel Promising Target for Diagnostic and Therapeutic Application. Aging Dis. 10 (6), 1302–1310. doi: 10.14336/AD.2018.1020
Triposkiadis, F., Xanthopoulos, A., Butler, J. (2019). Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 74 (6), 804–813. doi: 10.1016/j.jacc.2019.06.053
Tu, Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17 (10), 1217–1220. doi: 10.1038/nm.2471
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., et al. (2019). Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 29 (10), 787–803. doi: 10.1038/s41422-019-0216-x
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., et al. (2020). Geng et al. reply. Cell Res. 30 (9), 820. doi: 10.1038/s41422-020-0377-7
Keywords: medicinal plants, aging, age-related diseases, cardiovascular disease, neurodegenerative diseases
Citation: Liu Y, Echeverria V and Xu Y (2020) Editorial: Medicinal Plants for Cardiovascular and Neurodegenerative Aging-Related Diseases: From Bench to Bedside. Front. Pharmacol. 11:585155. doi: 10.3389/fphar.2020.585155
Received: 19 July 2020; Accepted: 11 September 2020;
Published: 23 September 2020.
Edited and reviewed by: Javier Echeverria, University of Santiago, Chile
Copyright © 2020 Liu, Echeverria and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yue Liu, bGl1eXVlaGVhcnRAaG90bWFpbC5jb20=